Cardiac kinin level in experimental diabetes mellitus: Role of kininases

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 1 54-1, 2003, Pages

  Koch, Matthias ^a   Wendorf, Michael ^a   Dendorfer, Andreas ^b   Wolfrum, Sebastian ^b   Schulze, Karsten ^a   Spillmann, Frank ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Bradykinin; Kininase; Myocardial ischemia

Indexed keywords

AMINOPEPTIDASE P; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; ENZYME INHIBITOR; KALLIKREIN; KININ; KININASE; KININOGEN; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; KALLIKREIN KININ SYSTEM; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; STREPTOZOCIN DIABETES;

EID: 0038338530     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00677.2002     Document Type: Article

References (43)

1. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, and Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 108: 293-295, 1993.
2. Bischoff A, Neumann A, Dendorfer A, and Michel MC. Is bradykinin a mediator of renal neuropeptide Y effects? Pfiügers Arch 438: 797-803, 1999.
3. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, and Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Spraque-Dawley and transgenic (mREN-2)27 rats. Kideney Int 56: 211-221, 1999.
4. 2-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 280: H1537-H1546, 2001.
5. Dendorfer A, Wolfrum S, Wageman M, Quadri F, and Dominiak P. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 280: H2182-H2188, 2001.
6. Dendorfer A, Wolfrum S, Wellhöner P, Korsman K, Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat. Br J Pharmacol 122: 1179-1187, 1997.
7. Ersahin C and Simmons WH. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol 30: 96-101, 1997.
8. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, and Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 80: 513-527, 2000.
9. Goyal RK, Satia MC, Bangaru RA, and Gandhi TP. Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats. J Cardiovasc Pharmacol 32: 317-322, 1998.
10. Groves P, Kurz S, Just H, and Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92: 3424-3430, 1995.
11. Hartman JC, Wall TM, Hullinger TG, and Shebuski RJ. Reduction of myocardial in farct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 21: 996-1003, 1993.
12. Hashimoto K, Hirose M, Furukawa K, Hayakawa H, and Kimura E. Changes in hemodynamic and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J 18: 679-680, 1977.
13. Jaffa AA, Chai KX, Chao J, Chao L, and Mayfield RK. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 41: 789-795, 1992.
14. Kiff RJ, Gardiner SM, Compton AM, and Bennett T. Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 103: 1357-1362, 1991.
15. Kimura E, Hashimoto K, and Furakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J 85: 635-647, 1973.
16. Kokkonen JO, Lindstedt KA, Kuoppala A, and Kovanan PT. Kinin-degrading pathways in the human heart. Trends Cardiovasc Med 10: 42-45, 2000.
17. 2 synthesis by diabetic coronary arteries. J Diabetes Complications 2: 5-7, 1988.
18. 9-bradykinin release following reperfusion of the ischemic rat heart. Br J Pharmacol 115: 476-478, 1995.
19. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
20. Mavrikakis ME, Sfikakis PP, Kontoyannis D, Horti M, Kittas C, Koutras DA, and Raptis SA. Macrovascular disease of coronaries and cerebral arteries in streptozotocin-induced diabetic rats. A controlled, comparative study. Exp Clin Endocrinol Diabetes 106: 35-40, 1998.
21. Mikrut K, Paluszak J, Kozlik J, Sosnowski P, Krauss H, and Grzeskowiak E. The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res Clin Pract 51: 79-85, 2001.
22. Nolly H, Carbini LA, Scicli G, Carretero OA, and Scicli AG. A local kallikrein-kinin system is present in hearts. Hypertension 23: 919-923, 1994.
23. Nolly H and Nolly A. Release of endothelial-derived kallikrein, kininogen and kinins. Biol Res 31: 169-74, 1998.
24. Okamoto H and Greenbaum LM. Isolation and properties of two rat plasma T-kininogens. Adv Exp Med Biol 198: 69-75, 1986.
25. Pitt B, Mason J, Conti CR, and Colman RW. Activation of the plasma kallikrein system during myocardial ischemia. Adv Exp Med Biol 8: 343-347, 1970.
26. Prechel MM, Orawski AT, Maggiora LL, and Simmons WH. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275: 1136-1142, 1995.
27. Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhoffer A, and Styk J. Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 210: 143-151, 2000.
28. Rösen P, Ballhaus T, and Stockklauer K. Impairment of endothelium-dependent relaxation in the diabetic heart: mechanisms and implications. Diabetes Res Clin Pract 31: S143-S155, 1996.
29. Rösen P, Rump AF, and Rösen R. Influence of angiotensin-converting enzyme inhibition by fosinopril on myocardial perfusion in streptozotocin-diabetic rats. J Cardiovasc Pharmacol 27: 64-70, 1996.
30. Sharma JN and Kesavarao U. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 33: 341-343, 1996.
31. Sharma JN, Uma K, and Yosof AP. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 63: 229-235, 1998.
32. Smith JM, Paulson DJ, and Romano FD. Inhibition of nitric oxide synthase by L-NAME improves ventricular performance in streptozotocin-diabetic rats. J Mol Cell Cardiol 29: 2393-2402, 1997.
33. 2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunol 2: 1823-1832, 2002.
34. 2-receptor expression at different time points after induction of myocardial infarction. J Hypertens 18: 223-228, 2000.
35. Tschöpe C, Heringer-Walther S, Koch M, Spillmann F, Wendorf M, Leistner E, Schultheiss HP, and Walther T. Up-regulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol 129: 1537-1538, 2000.
36. 2 receptor after induction of myocardial infarction. A mini-review. Braz J Med Biol Res 33: 701-708, 2000.
37. Tschöpe C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, and Unger T. Functional, biochemical, and molecular-biological investigations of renal kallikrein-kinin system in diabetic rats. Am J Physiol Heart Circ Physiol 277: H2333-H2340, 1999.
38. Tschöpe C, Walther T, Yu M, Reinecke A, Koch M, Seligmann C, Heringer S, Pesquero JB, Bader M, Schultheiss HP, and Unger T. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology 44: 35-42, 1999.
39. Vallejo S, Angulo J, Peiro C, Nevado J, Sanchez-Ferrer A, Petidier R, Sanchez-Ferrer CF, and Rodriguez-Manas L. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia 43: 83-90, 2000.
40. Warley A, Powell JM, and Skepper JN. Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats. Diabetologia 38: 413-21, 1995.
41. Wolfrum S, Dendorfer A, and Dominiak P. Identification of kallidin degrading enzymes in the isolated perfused rat heart. Jpn J Pharmacol 79: 117-120, 1999.
42. Wolfrum S, Richardt G, Dominiak P, Katus HA, and Dendorfer A. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol 134: 370-374, 2001.
43. Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, and Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 95: 1910-1917, 1997.